Testing a cancer drug for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign informed consent.
- Your cancer is advanced or has spread (metastatic) and is confirmed by the study team.
- Your general condition (ECOG) is 0 or 1, with no worsening in the 2 weeks before starting.
- You must provide a tumor tissue sample for lab testing during the study.
- You need at least one measurable tumor spot that has not been treated with radiation before (with a prostate-cancer exception for certain bone disease).
- You must have adequate blood counts/organ function and live at least 12 weeks, and follow study contraception rules (including negative pregnancy test if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new pill called DAT-2645 for people with advanced solid tumors that have a specific DNA repair problem (like a BRCA gene change). It aims to see if the drug is safe and effective when standard treatments have stopped working.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.